title: Activation of the leukotriene B4 receptor 2-reactive oxygen species (BLT2-ROS) cascade following detachment confers anoikis resistance in prostate cancer cells.
abstract: The majority of prostate cancer-related deaths are associated with advanced and metastatic malignancies. Although anoikis resistance has been recognized as one of the hallmarks of metastatic prostate malignancies, the molecular events that cause anoikis resistance are poorly understood. In this study, we found that the detachment of PC-3 prostate cancer cells caused a time-dependent increase in the expression level of the leukotriene B4 receptor-2 (BLT2) and that BLT2 played a critical role in establishing anoikis resistance in these cells. Blocking BLT2 with the pharmacological inhibitor LY255283 or with RNAi knockdown clearly abolished anoikis resistance and resulted in severe apoptotic death. Additionally, we demonstrated that the activation of NADPH oxidase (NOX) and subsequent generation of reactive oxygen species (ROS) were downstream of BLT2 signaling and led to the activation of NF-κB, thus establishing anoikis resistance during cell detachment. Furthermore, we observed that the ectopic expression of BLT2 in normal prostate PWR-1E cells rendered the cells resistant to anoikis and apparently diminished apoptotic cell death following detachment. Taken together, our results suggest that BLT2-NOX-ROS-NF-κB cascade induction during detachment confers a novel mechanism of anoikis resistance in prostate cancer cells and potentially contributes to prostate cancer progression.
authors.affiliation: From the College of Life Sciences and Biotechnology, Korea University, Seoul 136-701, Korea.
authors.forename: Jin-Wook
authors.initials: JW
authors.lastname: Lee
authors.affiliation: From the College of Life Sciences and Biotechnology, Korea University, Seoul 136-701, Korea. Electronic address: jhongkim@korea.ac.kr.
authors.forename: Jae-Hong
authors.initials: JH
authors.lastname: Kim
mesh_terms: D023102:Anoikis; D045744:Cell Line, Tumor; D006801:Humans; D020024:Leukotriene Antagonists / Q000494:pharmacology; D008297:Male; D019255:NADPH Oxidases / Q000235:genetics / Q000378:metabolism; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D034622:RNA Interference; D017382:Reactive Oxygen Species / Q000378:metabolism*; D018102:Receptors, Leukotriene B4 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction; D013777:Tetrazoles / Q000494:pharmacology
chemical_list: C485878:LTB4R2 protein, human; D020024:Leukotriene Antagonists; D016328:NF-kappa B; D009363:Neoplasm Proteins; D017382:Reactive Oxygen Species; D018102:Receptors, Leukotriene B4; D013777:Tetrazoles; D019255:NADPH Oxidases; C063823:LY 255283
keywords: Anokis Resistance; Apoptosis; Cancer; Cancer Biology; NADPH Oxidase; Prostate Cancer